Management of Postoperative Complications: New Generation Anticoagulation Usage In Thoracic Surgery and Management of Major Hemoptysis

January CT, Wann LS, Calkins H, Chen LY, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Managementof Patients With Atrial Fibrillation. Circulation 2019 Jan 28:CIR0000000000000665. [Epub ahead of print].

Lohrmann GM, Atwal D, Augoustides JG, Askar W, et al. Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the PerioperativePhysician. J Cardiothorac Vasc Anesth 2016;30:823-30.

Merli GJ, Hollander JE, Lefebvre P, Laliberté F, et al. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. J Med Econ 2016;19:84-90.

Shaikh SI, Kumari RV, Hegade G, Marutheesh M. Perioperative considerations and management of patients receiving anticoagulants. Anesth Essays Res 2017;11:10-6.

Mezue K, Obiagwu C, John J, Sharma A, et al. Novel oral anticoagulants in atrial fibrillation: update on apixaban. Curr Cardiol Rev 2017;13:41-6.

Ema T, Neyatani H, Yamamoto S, Iizuka S, et al. Postoperative hemorrhage after right upper lobectomy associated with apixaban use: a case report. AME Case Rep. 2018;2:46.

Hart BM, Ferrell SM, Motejunas MW, Bonneval LA, et al. New anticoagulants, reversal agents, and clinical considerations for perioperative practice. Best Pract Res Clin Anaesthesiol. 2018;32:165-178.

Lemay A, Kaye AD, Urman RD. Novel Anticoagulant Agents in the Perioperative Setting. Anesthesiol Clin. 2017;35:305-313.

Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018;15:273-81.

Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeut Clin Risk Manag 2015;11:967-77.

Eriksson BL, Quinlan DJ, Weitz JI, et al. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1–22.

Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13:362–367.

Ahmed AB, Koster A, Lance M, Faraoni D; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Cardiovascular and thoracic surgery. Eur J Anaesthesiol. 2018;35:84-89.

Widimský P, Moťovská Z, Havlůj L, Ondráková M, et al. Perioperative cardiovascular complications versus perioperative bleeding in consecutive patients with known cardiac disease undergoing non-cardiac surgery. Focus on antithrombotic medication. The PRAGUE-14 registry. Neth Heart J 2014;22:372-9.

Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667–74.

Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: AmericanCollege of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:89-119.

Shiroshita A, Nakashima K, Tanaka Y, Tateishi A, et al. Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report. J Thromb Thrombolysis. 2018;46:271-273.

Levy JH. Novel oral anticoagulation agents: new drugs create new paradigms. J Thorac Cardiovasc Surg. 2014;148:1802-3.

Earwood JS, Thompson TD. Hemoptysis: evaluation and management. Am Fam Physician. 2015;91:243-9.

Lee BR, Yu JY, Ban HJ, Oh IJ, et al. Analysis of patients with hemoptysis in a tertiary referral hospital. Tuberc Respir Dis 2012; 73: 107–114.

Abdulmalak C, Cottenet J, Beltramo G, Georges M, et al. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Respir J. 2015;46:503-11.

Hirshberg B, Biran I, Glazer M, Kramer M R. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112: 440–444.

Ong T H, Eng P. Massive hemoptysis requiring intensive care. Intensive Care Med 2003; 29: 317–320.

Soares Pires F, Teixeira N, Coelho F, Damas C. Hemoptysis— etiology, evaluation and treatment in a university hospital. Rev Port Pneumol 2011; 17: 7–14.

Lee J, Park YS, Lee CH, Lee SM, et al. Antiplatelet or anticoagulant therapy might not increase the risk of haemoptysis in patients with bronchiectasis. Int J Tuberc Lung Dis. 2013;17:989-91.

Elikowski W, Małek M, Skowroński M, Wróblewski D, et al. Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease. Pol Merkur Lekarski. 2015;39:227-30.